Helping ovarian cancer patients weigh PARP inhibitor treatment options
Gives patients with ovarian cancer a decision aid about PARP inhibitor maintenance treatment.
Key facts
- Who runs it
- University of Saskatchewan
- Where
- Saskatoon, CanadaSee the site
- Trial code
- Registry title
- Patient Preferences for Precision Medicine: Determining Optimal Patient Quality of Life Using PARPi's
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 17 Sept 2023
- Expected to end
- 16 Sept 2027
- Type of study
- Interventional
- Treatments tested
- Patients that are HRP are given a decision aid for PARPi use
- Record updated
- 27 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with known or suspected advanced ovarian cancer. It studies PARPi maintenance therapy, HRD testing and quality of life.
- Sex
- Women only
- Disease stage
- Known or suspected stage 3/4 high grade serous or endometrioid ovarian cancer.
- Biomarker or test result
- Must agree to HRD (homologous recombination deficiency) testing.
Main reasons for not taking part
- Cannot have maintenance PARPi therapy
- Refuses HRD testing
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Known or suspected stage 3/4 high grade serous or endometrioid ovarian cancer Able to provide oral consent and complete questionnaires in English as per study protocol
Who cannot take part
- Ineligible for Maintenace PARPi therapy Refusal to undergo HRD testing
Where in Canada
- Saskatchewan Cancer CenterSaskatoon, CanadaContact: Susan KabanTaking people
About the trial
What the trial wants to find out
Patients with ovarian cancer with defective DNA repair mechanisms derive substantial benefit from PARP inhibitor (PARPi) maintenance therapy. Both niraparib and olaparib are effective inhibitors of PARP, which exploit already defective DNA repair mechanisms (e.g., via BRCA mutations), particularly those with homologous recombination deficiency (HRD). These two PARPis have notably different toxicity profiles, with niraparib showing many more severe side effects. In this Ovarian Cancer Canada funded study, we will implement perform HRD testing for ovarian cancer patients in Saskatchewan with response to platinum-based chemotherapy. This information will provide personalized and precision estimates about the amount of benefit that can be expected from taking a PARPi. We will evaluate both treatment outcomes and quality of life in a real-world study setting, to inform future decision-making regarding efficacy, quality of life and cost-effectiveness of PARPi therapy, specifically for niraparib.
Read full original descriptionShow less
We hypothesize that for patients who are homologous recombinant proficient (HRP), the median 32.7-month incremental benefit (in delaying cancer progression) from taking a PARPi (niraparib is the only PARPi approved in this setting) will not be seen as being value-add when balanced by the decreased quality of life that accompanies the first 6-12 weeks of therapy. We also hypothesize that for women who are HRP, that PARPi therapy will not be cost-efficient.
The group in the trial
- HRD TestedOther group
HRP patients are given a decision aid, while HRD patients are not given a decision.
Treatment: Patients that are HRP are given a decision aid for PARPi use
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Patient Preferences for Precision Medicine
- Plain-language title
- Helping ovarian cancer patients weigh PARP inhibitor treatment optionsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 December 2024